HeartBeam (BEAT) Stock Price, News & Analysis

Company Overview

HeartBeam, Inc. develops wearable and digital cardiac-monitoring technologies designed to help detect and evaluate heart conditions outside traditional clinical settings. The company’s platform is intended to capture electrocardiogram (ECG) data in a portable, cable-free format and transmit that information through a connected mobile device.

HeartBeam’s technology is based on three-dimensional vector ECG recordings, which are designed to provide electrical views of the heart from multiple directions rather than relying solely on a conventional single-lead wearable reading. Its products are intended to support remote cardiac assessment, including the identification and monitoring of possible arrhythmias and other heart-related events.

The company’s lead product is the HeartBeam AIMIGo system, a compact personal ECG device that works with a smartphone application. HeartBeam was founded by Branislav Vajdic, who serves as chief executive officer. The company is based in Santa Clara, California, and its publicly described commercial and regulatory activities have primarily focused on the U.S. healthcare market.

Key Stats

• Today's Range: $0.40 to $0.43
• 50-Day Range: $0.40 to $0.66
• 52-Week Range: $0.39 to $4.00
• Volume: 288,006 shs
• Average Volume: 327,510 shs
• Market Capitalization: $22.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Moderate Buy

HeartBeam Stock Analysis - MarketRank™

HeartBeam scored higher than 51% of companies evaluated by MarketBeat, and ranked 475th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

HeartBeam has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

HeartBeam has a consensus price target of $4.00, representing about 892.8% upside from its current price of $0.40.

Amount of Analyst Coverage

HeartBeam has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HeartBeam are expected to grow in the coming year, from ($0.41) to ($0.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HeartBeam is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HeartBeam is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HeartBeam has a P/B Ratio of 6.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.20% of the float of HeartBeam has been sold short.

Short Interest Ratio / Days to Cover

HeartBeam has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in HeartBeam has recently decreased by 19.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HeartBeam does not currently pay a dividend.

Dividend Growth

HeartBeam does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for BEAT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added HeartBeam to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HeartBeam insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.95% of the stock of HeartBeam is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.77% of the stock of HeartBeam is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BEAT
• CIK: 1574774
• Web: www.gobio.com
• Phone: 610-729-7000
• Fax: N/A
• Employees: 1,700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HeartBeam: $4.00
• High Price Target: $5.50
• Low Price Target: $2.00
• Potential Upside/Downside: +892.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -686.78%
• Return on Assets: -348.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.66
• Quick Ratio: 3.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.06 per share
• Price / Book: 6.72

Miscellaneous

• Outstanding Shares: 56,350,000
• Free Float: 46,234,000
• Market Cap: $22.70 million
• Optionable: Not Optionable
• Beta: -0.80